Emergent BioSolutions Gets $1.25 Billion Contract to Supply Anthrax Vaccine

The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five years on a contract worth up to $1.25 billion.

Contract work will begin this year and calls for Emergent to deliver a total of 44.75 million doses of BioThrax. In the first contract year, 8.5 million doses are scheduled to be delivered. The vaccine will be delivered through September 2016.

The U.S. Food and Drug Administration has licensed BioThrax to protect against anthrax infection.

“This five-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs, ” said Emergent CEO Fuad El-Hibri.

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles